Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States

Diagnostic Microbiology and Infectious Disease

Volumn 51, Issue 1, 2005, Pages 31-37

  Bhavnani, Sujata M ^a,b,e   Hammel, Jeffrey P ^a,f   Jones, Ronald N ^c,d   Ambrose, Paul G ^a,b,e  

^a Albany Medical College   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c JMI LABORATORIES   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ORDWAY RESEARCH INSTITUTE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Fluoroquinolone resistance; Levofloxacin; Streptococcus pneumoniae; United States

Indexed keywords

LEVOFLOXACIN;

ANTIBIOTIC RESISTANCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONFERENCE PAPER; DATA ANALYSIS; DRUG USE; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HEALTH SURVEY; HOSPITAL BED CAPACITY; HUMAN; INFECTION SENSITIVITY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL SERVICE; MINIMUM INHIBITORY CONCENTRATION; OUTPATIENT CARE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL MODEL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 11144270151     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2004.08.017     Document Type: Conference Paper

References (39)

1. P.G. Ambrose, D.M. Grasela, T.H. Grasela, J. Passarell, H.B. Mayer, and P.F. Pierce Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections Antimicrob. Agents Chemother. 45 2001 2793 2797
2. K.B. Anderson, J.S. Tan, T.M. File Jr., J.R. DiPersio, B.M. Willey, and D.E. Low Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia Clin. Infect. Dis. 37 2003 376 381
3. S.E. Beekmann, K. Heilmann, C. Sauter, N. Miller, S.S. Richter, and G.V. Doern Increasing fluoroquinolone resistance in S. pneumoniae: An association with fluoroquinolone use Program and Abstracts of the Forty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003 2003 American Society for Microbiology Washington, DC 140 [Abstract C2-1498]
4. S.M. Bhavnani Resistance surveillance, pharmacokinetics/pharmacodynamics, and simulation: Can the use of old tools be improved to impact antibiotic resistance? Program and Abstracts of the Forty-First Infectious Diseases Society of America, San Diego, CA, 2003 2003 Infectious Diseases Society of America Alexandria, VA 33 [Speaker 1005]
5. S.M. Bhavnani, W.A. Callen, A. Forrest, K.K. Gilliland, D.A. Collins, J.A. Paladino, and J.J. Schentag Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals Am. J. Health Syst. Pharm. 60 2003 1962 1970
6. S.M. Bhavnani, J.P. Hammel, A. Forrest, R.N. Jones, and P.G. Ambrose Relationships between patient- and institution-specific variables and decreased susceptibility of Gram-negative pathogens Clin. Infect. Dis. 37 2003 344 350
7. A.B. Brueggemann, S.L. Coffman, P. Rhomberg, H. Huynh, L. Almer, A. Nilius, R. Flamm, and G.V. Doern Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995 Antimicrob. Agents Chemother. 46 2002 680 688
8. Centers for Disease Control and Prevention Defining the public health impact of drug-resistant Streptococcus pneumoniae: Report of a working group MMWR Morb. Mortal. Wkly. Rep. 45 1996 1 20
9. Centers for Disease Control and Prevention Resistance of Streptococcus pneumoniae to fluoroquinolones-United States, 1995-1999 MMWR Morb. Mortal. Wkly. Rep. 50 2001 800 804
10. D.K. Chen, A. McGeer, J.C. de Azavedo, and D.E. Low Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada N. Engl. J. Med. 341 1999 233 239
11. 24/MIC for 6 fluoroquinolones against Streptococcus pneumoniae with survival and bactericidal activity in an animal model Abstracts of the Fortieth Interscience Conference of Antimicrobial Chemotherapy, Toronto, Canada 2000 American Society for Microbiology Washington, DC 7 [Abstract 289]
12. R. Davidson, R. Cavalcanti, J.L. Brunton, D.J. Bast, J.C.S. de Azavedo, P. Kibsey, C. Fleming, and D.E. Low Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia N. Engl. J. Med. 346 2002 747 750
13. T.A. Davies, A. Evangelista, S. Pfleger, K. Bush, D.F. Sahm, and R. Goldschmidt Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000 Antimicrob. Agents Chemother. 46 2002 119 124
14. S.H. Gillespie, L.L. Voelker, J.E. Ambler, C. Traini, and A. Dickens Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation Microb. Drug Resist. 9 2003 17 24
15. J.D. Heffelfinger, S.F. Dowell, J.H. Jorgensen, K.P. Klugman, L.R. Mabry, D.M. Musher, J.F. Plouffe, A. Rakowsky, A. Schuchat, and C.G. Whitney Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group Arch. Intern. Med. 160 2000 1399 1408
16. P.L. Ho, T.L. Que, D.N. Tsang, T.K. Ng, K.H. Chow, and W.H. Seto Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong Antimicrob. Agents Chemother. 43 1999 1310 1313
17. P.L. Ho, W.S. Tse, K.W.T. Tsang, T.K. Kwok, T.K. Ng, V.C.C. Cheng, and R.M.T. Chan Risk factors for acquisition of levofloxacin resistant Streptococcus pneumoniae: A case-control study Clin. Infect. Dis. 32 2001 701 707
18. R.N. Jones, and M.A. Pfaller Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: Significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999) J. Clin. Microbiol. 38 2000 4298 4299
19. R.N. Jones, C.M. Rubino, S.M. Bhavnani, and P.G. Ambrose Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team Antimicrob. Agents Chemother. 47 2003 292 296
20. J.A. Karlowsky, C. Thornsberry, M.E. Jones, A.T. Evangelista, I.A. Critchley, and D.F. Sahm Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: Results from the TRUST Surveillance Program (1998-2002) Clin. Infect. Dis. 36 2003 963 970
21. M.B. Kays, D.W. Smith, M.E. Wack, and G.A. Denys Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia Pharmacotherapy 22 2002 395 399
22. M.A. Lacy, W. Lu, X. Xu, P.R. Tessier, D.P. Nicolau, R. Quintiliani, and C.H. Nightingale Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection Antimicrob. Agents Chemother. 43 1999 672 677
23. S. Lim, D. Blast, A. McGeer, J. de Azavedo, and D.E. Low Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: Redefining fluoroquinolone resistance Emerg. Infect. Dis. 9 2003 833 837
24. P.D. Lister Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: Impact of area under the curve/MIC ratios on eradication Antimicrob. Agents Chemother. 46 2002 69 74
25. P.D. Lister, and C.C. Sanders Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae J. Antimicrob. Chemother. 43 1999 79 86
26. P.D. Lister, and C.C. Sanders Pharmacodynamics of moxifloxacin, levofloxacin, and sparfloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model J. Antimicrob. Chemother. 47 2001 811 818
27. L.A. Mandell, T.J. Marrie, R.F. Grossmann, A.W. Chow, and R.H. Hyland Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group Clin. Infect. Dis. 31 2000 383 421
28. L.A. Mandell, J.G. Bartlett, S.F. Dowell, M. File Jr., D.M. Musher, and C. Whitney Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults Clin. Infect. Dis. 37 2003 1405 1433
29. J.E. McGowan Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use Rev. Infect. Dis. 5 1983 1033 1048
30. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing (Document M7-A6) 2003 NCCLS Wayne, PA
31. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing (Document M100-S14) 2004 NCCLS Wayne, PA
32. M.S. Niederman, L.A. Mandell, A. Anzueto, J.B. Bass, W.A. Broughton, G.D. Campbell, N. Dean, T. File, M.J. Fine, P.A. Gross, F. Martinez, T.J. Marrie, J.F. Plouffe, J. Ramirez, G.A. Sarosi, A. Torres, R. Wilson, V.L. Yu American Thoracic Society Guidelines for the management of adults with community-acquired lower respiratory tract infections: Diagnosis, assessment of severity, antimicrobial therapy and prevention Am. J. Respir. Crit. Care Med. 163 2001 1730 1754
33. R.C. Owens, and P.G. Ambrose Minimum efficacy and mutation prevention exposure target attainment rates against S. pneumoniae for standard-dose levofloxacin (500 mg) and high-dose levofloxacin (750 mg) and moxifloxacin Program and Abstracts of the Fortieth Infectious Diseases Society of America, Chicago, IL, 2002 2002 Infectious Diseases Society of America Alexandria, VA 56 [Abstract 67]
34. J.J. Ross, M.G. Worthington, S.L. Gorbach, G.S. Tillotson, X. Zhao, K. Drlica, G.G. Zhanel, D.J. Hoban, C.K. Chan, J. Hutchinson, D.E. Low, J. de Azavedo, and D. Bast Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia (letter) N. Engl. J. Med. 347 2002 65 67
35. H. Seppala, T. Klaukka, R. Lehtonen, E. Nenonen, and P. Huovinen Outpatient use of erythromycin: Link to increased erythromycin resistance in group A streptococci Clin. Infect. Dis. 21 1995 1378 1385
36. C. Thornsberry, M.E. Jones, M.L. Hickey, Y. Mauriz, J. Kahn, and D.F. Sahm Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998 J. Antimicrob. Chemother. 44 1999 749 759
37. C. Thornsberry, D.F. Sahm, L.J. Kelly, I.A. Critchley, M.E. Jones, A.T. Evangelista, and J.A. Karlowsky Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: Results from the TRUST Surveillance Program, 1999-2000 Clin. Infect. Dis. 34 Suppl. 1 2002 S4 S16
38. C. Urban, N. Rahman, X. Zhao, N. Mariano, S. Segal-Maurer, K. Drlica, and J.J. Rahal Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy J. Infect. Dis. 184 2001 794 798
39. G.W. Wortmann, and S.P. Bennett Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae Clin. Infect. Dis. 29 1999 1599 1600